At Advanced Orthodynamics Inc. we are committed to offering high quality, specialised orthotic service. We provide accurate assessment and evaluation using the latest equipment and methods, quality products fabricated with skill and care, as well as concise recording and communication of information to the referring health care professionals. Above all, we are dedicated to providing our clients with professional, consistent and courteous service.
http://www.spinalrestoration.com
Spinal Restoration, Inc. was formed through a strategic partnership between Austin Ventures, recognized as one of the top venture capital firms in the nation, and Path4 Ventures, a management centric venture capital firm focused on the musculoskeletal market. The partnership was formed to capitalize on opportunities for early intervention, minimally invasive therapies for the treatment of chronic back pain. The first endeavor is the Biostatâ„¢ Disc Augmentation System, a proprietary resorbable biologic compound and delivery system, for the treatment of chronic disc pain. The new treatment specifically targets disc pain which accounts for 40% of the 10 to 15 million patients that suffer from chronic low back pain annually. Spinal Restoration conservatively estimates the value of this market to be in excess of $2 billion annually. Spinal Restoration is built upon a world class team of clinical and scientific advisors, business partners and seasoned management. Lead by the President and CEO, Gary Sabins, the Management brings 80 years combined experience in pursuit of restoring patients' lives. Spinal Restoration and its partners share a passionate vision to address the needs of back pain sufferers around the world.
MicroSpine is dedicated to the research and treatment of spinal disorders by utilizing MicroSpine surgery (Also referred to as Minimally Invasive or Laser Endoscopic Spine Surgery). We can resolve most spinal disorders through a hole the size of your small finger (1/4 to 1/2 of an inch)4. Our staff employs Cutting Edge Technology to resolve the most troublesome spinal problems. If most surgeons tell you that they can't help you, then we probably can. Since our surgeries are minimally invasive, the amount of recovery time is less, the amount of scarring is less, and the post operative pain is less. In fact, 99.9% of our patients will be up and walking the same day as the surgery. Some call it a miracle, but it simply is the advancement of spinal surgery to the next degree. Just as with shoulder and knee surgeries that once required large incisions and long recovery times, these surgeries are now done on an outpatient basis. So it only employs common sense to utilize these less invasive endoscopic surgical techniques to the spine. Many surgeons claim they can perform similar procedures, but they do not. These surgeons will tell you they could perform such a surgery but it wouldn't help you and thus they'll offer you a fusion. In reality, only a small handful of surgeons in the world perform these MicroSpine procedures1 and our physicians have personally performed thousands of them3. Our location is not in a big city but it allows our staff to focus on spinal surgery and research and not to be burdened by medical and hospital politics. We are the only facility in the World dedicated to every aspect of minimally invasive spinal surgery. Yes, we are busy and you may have a short wait for surgery but good surgeons are busy. Be cautious of the surgeon who can get you in right way since there is probably a reason for their lack of patients. We design and manufacture our own tools and develop our own techniques, and we constantly monitor the literature to keep up to date on every aspect of evolving spine care. If it is cutting edge, then we probably do it. We have a complete staff of researchers and we have been regularly publicizing our data on our revolutionary techniques 2. So before you have any spinal surgery make sure you get all the facts about your options. Our staff will gladly review your MRI information and give you a free preliminary idea of what we believe we can offer you.
Founded in 2003, Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine. The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic and biomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc's design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms.
MediCepts, Inc. designs, produces, markets, and distributes high-quality innovative products and services for spinal wellness. The vision of MediCepts is to enable persons suffering from back pain to "live life without limitations." MediCepts' goal is to offer innovative spinal wellness, rehabilitation, exercise products and services that minimize pain and optimize function; that bring our patients into "spinal balance". MediCepts' first product, SPINE·SIX BIOMOTION SPINAL SYSTEMÔ, is an innovative multiplanar spinal motion system that allows for "six degrees of freedom" in movement for both cervical and lumbar patients. MediCepts, Inc. is a wholly-owned subsidiary of SunCepts, Inc. of Stuart, Florida.
Axial Biotech, Inc. is focused on the use of genetics and the development of minimally invasive, motion preserving implants to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is the first company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial product development initiative, Axial has made significant progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five fusionless surgical devices (including the only such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its proprietary genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Spine care has historically focused on ameliorating the pain and/or fixing structural damage after it occurs. Recent technological advances in minimally invasive surgical techniques and better instrumentation have made the spine industry the hottest segment of the medical device market today, according to Start-Up magazine. Market analysis indicates a $3 billion sales potential for new instrumentation alone within 4 years, with this market compounding at greater than 20% per year. In the last 24 months, over $250 million of reported venture capital financing has flowed into spine start-ups and investors have achieved exits totaling over $1 billion, including one IPO (NuVasive). Axial's novel tests will complement the advances in surgical instrumentation by providing the spine care industry with the first to market diagnostic and prognostic tests for targeting earlier and more appropriate therapeutic interventions. Axial's surgical devices, one of which is currently in off-label use in humans, represent the only available alternative to spine fusion in the treatment of scoliosis. Axial is located in Salt Lake City, Utah, a place the New York Times recently called "an ideal genetic laboratory."
Paradigm Spine is a provider of non-fusion spinal implant solutions that serve to address the unmet clinical needs of spine surgeons and their patients. Starting with the coflex interspinous implant technology Paradigm Spine develops a full non-fusion product portfolio of motion preserving, tissue sparing technologies. It is our commitment to lead the positioning of non-fusion technologies to the forefront of improving the quality of life in patients with spinal diseases through being surgeon centric, indication specific and data driven.
OBI, located in San Antonio, Texas, is a private company that develops and manufactures bioabsorbable polymeric scaffolds, films, and related instrumentation for the repair and replacement of bone, soft tissue and articular cartilage. Its products are based on proprietary and patented technologies covered by U.S. and foreign patents.
BioMimetic Therapeutics, Inc. (BioMimetic) is developing and commercializing regenerative protein therapeutic-device combination products that have the potential to improve the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments and cartilage. The Company’s platform regenerative technology, which incorporates a synthetic and potent version of one of the body’s natural stimulators of tissue repair, may offer physicians and dentists the biological solutions to actively stimulate tissue healing and regeneration. BioMimetic is in the final phases of its orthopedic clinical trials. If approved by the appropriate regulatory authorities, its product candidates will offer effective and less invasive treatment options in orthopedics, spine and sports related injuries. (Source: 10-K)
Biorthex Inc. is a biotechnology company that designs, develops, manufactures and markets innovative and proprietary surgical products for the treatment of spinal disorders. The Company is dedicated to providing the surgical community with safe, technologically proven and innovative spinal implants for use in the treatment of spinal disorders, diseases and injuries. Our mission at Biorthex is to develop and market breakthrough products, which will enhance the practice of orthopaedic surgeons and associated healthcare professionals and thus, the quality of life of their patients. In 1997, Biorthex commenced development of a porous nickel-titanium alloy, Actipore, to address the challenge of host bone to implant fixation. Several years of research and development resulted in the production of a unique ultra porous, biologically and biomechanically compatible nitinol material. The material's isotropic porous structure, with inherent capillary wicking pores, draws essential fluids and nutrients into the material thus facilitating bone cell penetration and survival and allowing strong, rapid growth of newly forming bone cells through its scaffold (three dimensional networks of pores). With similar mechanical properties to bone resulting in load sharing, as well as MRI and CT scan compatibility, the abovementioned qualities lent themselves ideally to the production of spinal interbody devices. As a consequence, the Actipore interbody device project was born. The use of Biorthex's innovative interbody fusion material, Actipore, enables a less invasive surgical procedure which may shorten hospital stay and/or accelerate patient recovery and as a consequence, may allow a reduction of overall cost of treatment compared to traditional methods. Studies conducted so far indicate a fusion rate which is at least as good as competitors' devices. Biorthex offers three products derived from its Actipore technology, two of them are advanced interbody fusion device indicated for lumbar fusion : the Actipore PLFx system and the Actipore PLF system, the third Actipore ACF system is indicated for cervical fusion. Biorthex is currently developing a fourth interbody fusion device, called Actipore ALF for lumbar fusion via anterior approach.
SpineMark Corporation is an innovative service organization dedicated to transforming the delivery of spine care. The company partners with hospitals and physicians across the United States and globally to develop and operate comprehensive, evidence-based spine centers of excellence. By building a global network of spine centers, spine research organizations and state-of-the-art medical conference facilities, SpineMark is improving the overall quality of life of patients afflicted with spine disorders and injuries. Driven by the specialized experience and expertise of its leadership team and Medical Advisory Board, SpineMark maintains high standards for spine care in its global network, creating clinically validated best practices for spine care that streamline diagnosis and treatment, simplify referrals and accelerate the recovery process.
Innovative Spinal Technologies (IST) develops innovative spine products and services through intellectual property development and product development. IST works closely with the Texas Back Institute (TBI) and other leading clinicians to develop state-of-the-art products for the spine industry. IST was founded in 2002 by TBI and spine surgeons Stephen Hochschuler, MD and Barton Sachs, MD, MBA.
http://www.synthes-stratec.com
Synthes-Stratec is a leading provider of instruments, implants and power tools for the orthopaedic trauma market. The company competes in North and Latin America and parts of Europe. The company develops, manufactures and distributes products for the surgical treatment of bone fractures, maxillofacial trauma or deformities, and a full range of products and systems for spine surgery. Synthes-Stratec also develops, manufactures and distributes prosthetics products and systems for computer-assisted surgery, mainly throughout Europe. The prosthetics product lines are in the early stages of market development.
TranS1 Inc. (TranS1) is medical device company focused on designing, developing and marketing products that implement its minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine. Using this TranS1 approach, a surgeon can access discs in the lower lumbar region of the spine through a 1.5 centimeters incision adjacent to the tailbone and can perform an entire fusion procedure through a small tube that provides direct access to the degenerative disc. The Company developed its TranS1 approach to allow spine surgeons to access and treat degenerative lumbar discs without compromising important surrounding soft tissue. AxiaLIF and AxiaLIF 360°, two single-level fusion products the TranS1 has developed, are being marketed by the Company in the United States and Europe. AxiaLIF 2L, a two level fusion product developed by TranS1, is also marketed in Europe. (Source: 10-K)
Smith & Nephew plc is a global medical devices company engaged in the development, manufacture and marketing of medical devices in the sectors of orthopedic reconstruction, orthopedic trauma and clinical therapies, endoscopy and advanced wound management. It has four business segments: reconstruction, trauma and clinical therapies, endoscopy and advanced wound management. Reconstruction implants offered include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Its trauma and clinical therapies products comprise both trauma fixation products and associated clinical therapies. Its endoscopy business develops and commercializes endoscopic (minimally invasive surgery) techniques and value-added services for surgeons to treat and repair soft tissue and articulating joints. Its advanced wound management business offers products from initial wound bed preparation through to full wound closure. (Source: 20-F)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory